Clinical trial NCT05320523: Simultaneous DBS of the GPi and the NBM in Patients With Parkinson's Disease and Mild Cognitive Impairment
Official title: Simultaneous Deep Brain Stimulation of the Globus Pallidus Internus and the Nucleus Basalis of Meynert in Patients With Parkinson's Disease and Mild Cognitive Impairment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Parkinson Disease
Mild Cognitive Impairment
Keywords: Parkinson's disease
Mild cognitive impairment
Globus Pallidus internus (GPi) Stimulation
Nucleus basalis of Meynert (NBM) Stimulation
Deep Brain Stimulation (DBS)
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
First posted: 2022-04-11
Enrollment: 10
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase 1 study evaluating the safety of combined bilateral globus pallidus internus (GPi) and nucleus basalis of Meynert (NBM) stimulation in treating levodopa responsive motor symptoms of Parkinsonism and cognitive dysfunction, respectively, in patients with moderate to advanced Parkinson's disease having mild cognitive impairment.

Detailed description: This study aims to provide a proof of safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease having mild cognitive impairment.

GPi stimulation with high-frequency ameliorates the cardinal motor symptoms and motor complications in Parkinson's disease patients, and this present study also wants to determine if additional NBM stimulation, with low-frequency stimulation, improves or slows progression of cognitive decline in patients with moderate to advanced Parkinson's disease having mild cognitive impairment, and to evaluate the effect of NBM stimulation on gait and balance impairment.

Study Design: Prospective single center Phase 1 study with double-blind randomized delayed activation of basal nucleus of Meynert neurostimulation (staggered onset design).

Planned Number of Subjects: 10 patients.

Planned Number of Sites / Countries: Single center in Brazil.

Study schedule:

* Presurgical baseline evaluation (motor on and off medication state; cognitive testing in best motor on state).
* DBS Implant Procedure.
* Postsurgical baseline evaluation (motor off state; cognitive testing in best motor on state) at 3±1 weeks after surgery and activation of globus pallidus internus neurostimulation using individualized stimulation parameters after a standard monopolar review.
* Regular adjustments of the GPi stimulation parameters aiming at the best motor improvement.
* Visit 1 (16 weeks after activation of GPi neurostimulation): motor off medication + GPi stimulation state, cognitive testing in on medication + GPi stimulation state. Randomization and blinded activation of NBM neurostimulation according to a 1:1 scheme.
* Visit 2 (16 weeks after randomization): motor off and on medication + stimulation state (GPi stimulation ± NBM stimulation); cognitive testing in motor on medication + stimulation state (GPi stimulation ± NBM stimulation). Activation of NBM neurostimulation in all patients.
* Visit 3 (16 weeks after activation of NBM stimulation in all patients): motor off and on medication + GPi and NBM stimulation state; cognitive testing in motor on medication + GPi and NBM stimulation state.
* Annual follow-up visit for up to 5 years after activation of NBM stimulation.

Eligibility criteria: Inclusion Criteria:

* Age at the time of enrollment: 50 - 75 years.
* Diagnosis of idiopathic PD according to Movement Disorders Society (MDS) criteria (Albanese et al., 2017).
* Mild cognitive impairment (MCI) related to Parkinson's disease according to MDS criteria. (Livtan et al. 2012).
* Duration of bilateral idiopathic PD: ≥ 5 years of motor symptoms.
* Modified Hoehn and Yahr stage ≥ 2 on off medication state.
* UPDRS subset III (motor) ≥ 30 points on off medication state.
* Levodopa must improve PD symptoms by ≥ 30% in a levodopa challenge test, as measured by UPDRS subset III score.
* Presence of motor complications related to Parkinson's disease.
* Be willing and able to comply with all visits and study related procedures
* Able to understand the study requirements and the treatment procedures and to provide written informed consent before any study-specific tests or procedures are performed.

Exclusion Criteria:

* Alcohol or drug abuse.
* Any significant psychiatric problems, including acute confusional state (delirium), ongoing psychosis, or clinically significant depression.
* Contraindications for deep brain stimulation (DBS) surgery.
* Heart failure, heart disease or any condition that contraindicates surgical procedures.
* Pacemaker or other active implanted stimulators.
* Clearly established Parkinson's disease dementia according to Movement Disorders Criteria.
* Participation in another drug, device, or biologics trial concurrently.

Primary outcomes:
measure: Safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease with mild cognitive impairment as determined by reported adverse events.
timeFrame: 36 weeks
Secondary outcomes:
measure: Change in Parkinson's Disease - Cognitive Rating Scale (PD-CRS).
timeFrame: 36 weeks
measure: Change in Mattis Dementia Rating Scale.
timeFrame: 36 weeks
measure: Change in Verbal Fluency Battery.
timeFrame: 36 weeks
measure: Change in Trail Making Task.
timeFrame: 36 weeks
measure: Change in Stroop Test.
timeFrame: 36 weeks
measure: Change in Symbol Digit Modalities Test.
timeFrame: 36 weeks
measure: Change in Parkinson's Disease Questionnaire for quality of life (PDQ-39).
timeFrame: 36 weeks
measure: Change in Questionnaire of the EuroQol-group (EQ-5D-5L).
timeFrame: 36 weeks
measure: Change in Unified Parkinson's Disease Rating Scale section I (UPDRS I).
timeFrame: 36 weeks
measure: Change in Unified Parkinson's Disease Rating Scale section II (UPDRS II).
timeFrame: 36 weeks
measure: Change in Unified Parkinson's Disease Rating Scale section III (UPDRS III).
timeFrame: 36 weeks
measure: Change in Unified Parkinson's Disease Rating Scale section IV (UPDRS IV).
timeFrame: 36 weeks
measure: Change in objective assessment of gait measured by a sensor (MobilityLab) that assess step speed.
timeFrame: 36 weeks
measure: Change in objective assessment of gait measured by a sensor (MobilityLab) that assess number of steps per minute.
timeFrame: 36 weeks
measure: Change in objective assessment of gait measured by a sensor (MobilityLab) that assess distance between heels.
timeFrame: 36 weeks
measure: Change in objective assessment of gait measured by a sensor (MobilityLab) that assess balance.
timeFrame: 36 weeks
measure: Change in objective assessment of gait measured by Time Up and Go - Test 3 meters (TUG test 3M).
timeFrame: 36 weeks
measure: Change in objective assessment of gait measured by Time Up and Go dual task - Test 3 meters (TUG dual task - test 3M).
timeFrame: 36 weeks
measure: Change in objective assessment of gait measured by freezing of gait score (FOG score).
timeFrame: 36 weeks
measure: Change in New Freezing of Gait Questionnaire (N-FOG).
timeFrame: 36 weeks
measure: Change in Falls Efficacy Scale International (FES-I).
timeFrame: 36 weeks
measure: Change in Activities-Specific Balance Confidence Scale (ABC scale).
timeFrame: 36 weeks
measure: Change in Beck Depression Inventory (BDI).
timeFrame: 36 weeks
measure: Change in Beck Anxiety Inventory (BAI).
timeFrame: 36 weeks
measure: Change in Starkstein Apathy Scale.
timeFrame: 36 weeks
measure: Change in Neuropsychiatric Inventory (NPI).
timeFrame: 36 weeks
measure: Change in Ardouin Scale of Behavior in Parkinson's Disease.
timeFrame: 36 weeks
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: University of São Paulo General Hospital
Study officials:
References:
citation: Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Limousin P, Hariz M, Jahanshahi M, Foltynie T. Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2018 Feb 1;75(2):169-178. doi: 10.1001/jamaneurol.2017.3762.
citation: Nombela C, Lozano A, Villanueva C, Barcia JA. Simultaneous Stimulation of the Globus Pallidus Interna and the Nucleus Basalis of Meynert in the Parkinson-Dementia Syndrome. Dement Geriatr Cogn Disord. 2019;47(1-2):19-28. doi: 10.1159/000493094. Epub 2019 Jan 10.
citation: Sankar T, Lipsman N, Lozano AM. Deep brain stimulation for disorders of memory and cognition. Neurotherapeutics. 2014 Jul;11(3):527-34. doi: 10.1007/s13311-014-0275-0.
citation: Kuhn J, Hardenacke K, Lenartz D, Gruendler T, Ullsperger M, Bartsch C, Mai JK, Zilles K, Bauer A, Matusch A, Schulz RJ, Noreik M, Buhrle CP, Maintz D, Woopen C, Haussermann P, Hellmich M, Klosterkotter J, Wiltfang J, Maarouf M, Freund HJ, Sturm V. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer's dementia. Mol Psychiatry. 2015 Mar;20(3):353-60. doi: 10.1038/mp.2014.32. Epub 2014 May 6.
citation: Freund HJ, Kuhn J, Lenartz D, Mai JK, Schnell T, Klosterkoetter J, Sturm V. Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation. Arch Neurol. 2009 Jun;66(6):781-5. doi: 10.1001/archneurol.2009.102.
citation: Wilson J, Yarnall AJ, Craig CE, Galna B, Lord S, Morris R, Lawson RA, Alcock L, Duncan GW, Khoo TK, O'Brien JT, Burn DJ, Taylor JP, Ray NJ, Rochester L. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease. Mov Disord. 2021 Mar;36(3):611-621. doi: 10.1002/mds.28453. Epub 2020 Dec 31.
citation: Muller ML, Bohnen NI. Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep. 2013 Sep;13(9):377. doi: 10.1007/s11910-013-0377-9.
citation: Gratwicke J, Zrinzo L, Kahan J, Peters A, Brechany U, McNichol A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Crutch SJ, Taylor JP, McKeith I, Rochester L, Schott JM, Limousin P, Burn D, Rossor MN, Hariz M, Jahanshahi M, Foltynie T. Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. Brain Stimul. 2020 Jul-Aug;13(4):1031-1039. doi: 10.1016/j.brs.2020.04.010. Epub 2020 Apr 22.
citation: Dalrymple WA, Huss DS, Blair J, Flanigan JL, Patrie J, Sperling SA, Shah BB, Harrison MB, Druzgal TJ, Barrett MJ. Cholinergic nucleus 4 atrophy and gait impairment in Parkinson's disease. J Neurol. 2021 Jan;268(1):95-101. doi: 10.1007/s00415-020-10111-2. Epub 2020 Jul 28.
citation: Koulousakis P, Andrade P, Visser-Vandewalle V, Sesia T. The Nucleus Basalis of Meynert and Its Role in Deep Brain Stimulation for Cognitive Disorders: A Historical Perspective. J Alzheimers Dis. 2019;69(4):905-919. doi: 10.3233/JAD-180133.